Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer

Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma. The date of the last biopsy that verifies that the eligibility criterions have been met must be within 9 months prior to randomization. There must be no prior treatment. * Intermediate-risk cancer patients based on the NCCN Guidelines (www.nccn.org): • TNM classification: * T2b-T2c and Gleason Score \< 8/10 and PSA \< 20 ng/ml; or * T1c-T2a and Gleason Score 7/10 and PSA \< 20 ng/ml; or * T1c-T2a and Gleason Score ≤ 6/10 and 10 ≤ PSA \< 20 ng/ml For patients who have been on alpha reductase inhibitors within the last 6 months, use the following guidelines: * T2b-T2c and Gleason Score \< 8/10 and PSA ≤ 10 ng/ml; or * T1c-T2a and Gleason Score 7/10 and PSA ≤ 10 ng/ml; or * T1c-T2a and Gleason Score ≤ 6/10 and 5 ≤ PSA ≤ 10 ng/ml * No alpha reductase inhibitors (i.e. avodart, proscar) use within 2 weeks of randomization. A washout period of 2 weeks is required prior to randomization. * Prostate volume ≤ 75 cc. * American Urological Association (AUA) Symptom Index score \< 20. * Judged to be medically fit for IGRT and HDR brachytherapy boost by a radiation oncologist. * ECOG Performance Status of 0 or 1. * ≥ 18 years of age. * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate. * Patients must be accessible for treatment and follow…